RxDoctor Payments Data

Shyamal Bastola, MD

Hematology & Oncology · Zanesville, OHNPI 1306003033

Payments from drug & device makers

$471,718in general payments, 2019–2025

Across 87 payments — averaging $5422.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$301K
  • AbbVie$83K
  • Seagen Inc.$61K
  • AstraZeneca$10K
  • Amgen$4K
  • Novartis$2K
  • plus $10K from 16 others

What the payments were for

  • Consulting fees$15,78881%
  • Speaking & faculty fees$2,87515%
  • Food & beverage$280%
  • Education$7814%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$471,718 in reported general payments places this provider in the 80th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$236,481
Medicare patients
639
Services billed
2,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate49$737,609
BrukinsaZanubrutinib42$613,841
CabometyxCabozantinib S-Malate24$575,285
Lenalidomide39$568,621
TasignaNilotinib Hcl27$542,355
KisqaliRibociclib Succinate30$468,401
TagrissoOsimertinib Mesylate15$236,566
XtandiEnzalutamide13$186,578
Abiraterone Acetate65$182,808
EliquisApixaban179$138,224
CresembaIsavuconazonium Sulfate16$99,504
InrebicFedratinib Dihydrochloride13$86,275
VenclextaVenetoclax25$69,384
XareltoRivaroxaban41$29,156
Exemestane47$7,665

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisTasigna, Kisqali$2,489$1,010,75557 claims
Incyte CorporationJakafi$274$737,60949 claims
Beigene USA, Inc.Brukinsa$675$613,84142 claims
Exelixis Inc.Cabometyx$98$575,28524 claims
AstraZenecaTagrisso$9,597$236,56615 claims
PfizerEliquis$882$138,224179 claims
AbbVieVenclexta$83,474$69,38425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Zanesville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →